Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America

The Kirby Institute, The University of New South Wales, Sydney, NSW, Australia.
Journal of the International AIDS Society (Impact Factor: 5.09). 01/2012; 15(1):5. DOI: 10.1186/1758-2652-15-5
Source: PubMed


The objective was to examine the short-term risk and predictors of anaemia following initiation of combination antiretroviral therapy (cART) in HIV-infected patients from the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration.
Anaemia was defined as haemoglobin of < 10 g/dL. Patients were included if they started cART with three or more drugs, had prior haemoglobin of > = 10 g/dL, and had one or more follow-up haemoglobin tests. Factors associated with anaemia up to 12 months were examined using Cox proportional hazards models and stratified by IeDEA region.
Between 1998 and 2008, 19,947 patients initiated cART with baseline and follow-up haemoglobin tests (7358, 7289, 2853, 471, 1550 and 426 in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian-Pacific, and Caribbean and Central and South America regions, respectively). At initiation, anaemia was found in 45% of Western Africa patients, 29% of Eastern Africa patients, 21% of Southern Africa patients, 36% of Central Africa patients, 15% of patients in Asian-Pacific and 14% of patients in Caribbean and Central and South America. Among patients with haemoglobin of > = 10 g/dL at baseline (13,445), the risks of anaemia were 18.2, 6.6, 9.7, 22.9, 11.8 and 19.5 per 100 person-years in the Western Africa, Eastern Africa, Southern Africa, Central Africa, Asian, and Caribbean and Central and South America regions, respectively. Factors associated with anaemia were female sex, low baseline haemoglobin level, low baseline CD4 count, more advanced disease stage, and initial cART containing zidovudine.
In data from 34 cohorts of HIV-infected patients from sub-Saharan Africa, Central and South America, and Asia, the risk of anaemia within 12 months of initiating cART was moderate. Routine haemoglobin monitoring was recommended in patients at risk of developing anaemia following cART initiation.

Download full-text


Available from: Kara Wools-Kaloustian,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anemia is the main concern among patients using a zidovudine (AZT)-based antiretroviral treatment (ART). Some studies suggested weight-adjusted AZT dosing as a way to reduce toxicity. We analyzed the risk factors associated with AZT-induced anemia in a cohort using AZT as substitution for stavudine (D4T). We retrospectively studied HIV-infected patients in a referral hospital in Phnom Penh, Cambodia between 2003 and 2011. Factors associated with AZT-related anemia requiring AZT-discontinuation within the first year after AZT initiation were analyzed using Cox regression. Overall, 1180 patients, 60.5% female, were included. At AZT initiation, the median hemoglobin was 12.7 g/dL (IQR 11.7-13.9), the median weight: 51 kg (IQR 45-58) and the median time on ART prior to AZT substitution: 1.4 years (IQR 1.0-2.0). Within one year follow-up, 139 patients (11.8%) developed anemia requiring AZT discontinuation. Overall, there was no independent association of body weight with AZT discontinuation. AZT discontinuation was associated with lower hemoglobin level when starting AZT; older age and taking D4T-based ART less than one year prior to AZT. In exploratory analysis, a linear increase in risk of grade 2-4 anemia with lower body weight was seen if starting AZT substitution within less than one year of D4T-based ART. Our findings argue against the need of weight-based dosing of AZT to reduce anemia among patients using AZT as substitution for D4T. Whether this also applies to ART-naïve individuals remains to be assessed. Future studies with AZT dose reduction should assess efficacy and overall tolerance of AZT.
    PLoS ONE 03/2013; 8(3):e60206. DOI:10.1371/journal.pone.0060206 · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The strengthening of generic drugs policy may be accompanied by reservations about their quality, and therefore, also about effectiveness of some of these products. Phase IV clinical trials are a proper design to evaluate the effectiveness and safety of these drugs. Objective: Assess the effectiveness and the safety data of generic drug scheme Lamivudine/Zidovudine/Efavirenz in HIV (+) naïve patients who are served in a specialized comprehensive ambulatory care program, and compare these results with efficacy and safety data reported in reference studies (using the same therapeutic scheme of innovator drugs and conducted in patients with the same conditions). Methods: An open-label and non-controlled phase IV clinical trial was conducted. Effectiveness (measured as viral load reduction to undetectable level and lymphocytes CD4 + increase) and safety (adverse reactions) of the generic drug scheme Lamivudine/Zidovudine + Efavirenz were assessed. Antiretroviral therapy was used during 12 months in HIV (+) naïve patients over 18 years old who had the indication to treatment. Clinical follow-up and Pharmacotherapy follow-up were used as assessment strategies and data collection. Non-inferiority hypothesis was contrasted against the study results and those reported in a reference study. Results: The study included 47 patients, of which 33 completed the study. After one year of treatment, 28 patients (85%) achieved a statistically significant reduction in viral load (assessed by undetectable mRNA copies/mL), and 30 of them (91%) had a progressive and statistically significant increase in T- CD4 + lymphocyte count greater than 200 cells/mm3. The comparison was performed using an article that met the defined criteria, and non-inferiority hypothesis was proven. The proportions of patients [CI 95%] achieving undetectability was not statistically different when comparing with reference study: 0.85 [0.69 to 0.93] versus 0.90 [0.81 to 0.93], p = 0.7. Similarly, there was no difference in the average increase of CD4 + [SD]: 179 ± 142 versus 201 ± 21, p = 0.08. Likewise, No important differences in the safety profile were found. Conclusions: The generic drug scheme Lamivudine/Zidovudine/Efavirenz is effective and safe, and effectiveness outcomes achieved were not lower than those reported in reference studies designed to assess the same scheme of innovator drugs.
    Vitae 04/2013; 20(1):30-40. · 0.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and Methods This cross-sectional study aimed at determining the prevalence and risk factors for severe anemia, severe microcytic anemia, and severe normocytic anemia among HIV-infected individuals aged >15 years. Univariate and multivariate analyses were performed to identify the risk factors for anemia.ResultsData from 40 408 patients were analyzed, showing an overall prevalence of 22% for severe anemia. The risk of developing severe anemia increased by 49% among patients with a body mass index of <18.5 kg/m(2), by approximately 2-fold among patients with the World Health Organization (WHO) stage III, and by 3-fold among patients with WHO stage IV illness. Severe normocytic anemia was uniquely increased among patients aged ≥50 years, among those with chronic diarrhea and Kaposi sarcoma, and those taking cotrimoxazole.Conclusion There was a high prevalence of severe anemia among adults infected with HIV. Focused identification of anemia should be based on the hemoglobin and mean corpuscular volume measurements.
    Journal of the International Association of Providers of AIDS Care 06/2013; 14(2). DOI:10.1177/2325957413488195
Show more